Microsemi Corporation (MSCC) Drops 6.38% on January 18

Equities Staff  |

Microsemi Corporation (MSCC) was one of the Russell 2000's biggest losers for Monday January 18 as the stock slid 6.38% to $29.77, a loss of $-2.03 per share. Starting at an opening price of $30.79 a share, the stock traded between $29.77 and $31.04 over the course of the trading day. Volume was 15.61 million shares over 22,635 trades, against an average daily volume of 1.05 million shares and a total float of 96.2 million.

The losses send Microsemi Corporation down to a market cap of $2.86 billion. In the last year, Microsemi Corporation has traded between $39.56 and $25.36, and its 50-day SMA is currently $34.25 and 200-day SMA is $34.12.

The stock has a P/E Ratio of 33.8.

Microsemi Corp is a designer, manufacturer and marketer of analog and mixed-signal semiconductor solutions.

Microsemi Corporation is based out of Aliso Viejo, CA and has some 3,700 employees. Its CEO is James J. Peterson.

For a complete fundamental analysis analysis of Microsemi Corporation, check out Equities.com’s Stock Valuation Analysis report for MSCC. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Joseph Weinberg CEO PayCase, Chairman Shyft

Matt Bird sits down with Joseph Weinberg CEO PayCase, Chairman Shyft at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.